[
  {
    "ts": null,
    "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
    "url": "https://finnhub.io/api/news?id=d94cacec40d8bf68f98f0616ed737720b9ab95b18723e069473fb6502b70dd3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772291278,
      "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
      "id": 139264510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
      "url": "https://finnhub.io/api/news?id=d94cacec40d8bf68f98f0616ed737720b9ab95b18723e069473fb6502b70dd3a"
    }
  },
  {
    "ts": null,
    "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "summary": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772266200,
      "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
      "id": 139262332,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457"
    }
  },
  {
    "ts": null,
    "headline": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with […]",
    "url": "https://finnhub.io/api/news?id=233d87f0e1dfd5bf5c89fa505448f7ca43e8e6e08a683193c2d6459d3907a6d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772263304,
      "headline": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds",
      "id": 139261000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with […]",
      "url": "https://finnhub.io/api/news?id=233d87f0e1dfd5bf5c89fa505448f7ca43e8e6e08a683193c2d6459d3907a6d9"
    }
  },
  {
    "ts": null,
    "headline": "Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?",
    "summary": "Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.",
    "url": "https://finnhub.io/api/news?id=f44c7d3cd8ea6924b8f3e8d2258352c770c2bc81cce05727b6a8fd28ed405d8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772255996,
      "headline": "Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?",
      "id": 139261614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.",
      "url": "https://finnhub.io/api/news?id=f44c7d3cd8ea6924b8f3e8d2258352c770c2bc81cce05727b6a8fd28ed405d8e"
    }
  }
]